|
1) Sellebjerg F, Barnes D, Filippini G, et al. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol. 2005; 12: 939-46
|
|
|
|
2) Rieckmann P, Toyka KV, Bassetti C, et al. Escalating immunotherapy of multiple sclerosis-new aspects and practical application. J Neurol. 2004; 251: 1329-39
|
|
|
|
|
|
3) Chataway J, Porter B, Riazi A, et al. Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomized controlled trial. Lancet Neurol. 2007; 5: 565-71
|
|
|
|
|
|
4) Glass-Marmor, Paperna T, Ben-Yosef Y, et al. Chronotherapy using corticosteroids for multiple sclerosis relapses. J Neurol Neurosurg Psychiatry. 2007; 78: 886-8
|
|
|
|
|
|
5) Schilling S, Linker RA, Konig FB, et al. Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients. Nervenarzt. 2006; 77: 430-8
|
|
|
|
|
|
6) Keegan M, Konig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet. 2005; 366: 579-82
|
|
|
|
|
|
7) Bermel RA, Rudick RA. Interferon-β treatment for multiple sclerosis. Neurotherapeutics. 2007; 4: 633-46
|
|
|
|
|
|
8) Kinkel RP, Kollman C, O'Corner P, et al. IM interferon beta -1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006; 66: 678-84
|
|
|
|
|
|
9) Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite McDonald MS in patients with clinically isolated syndrome. Neurology. 2006; 67: 1242-9
|
|
|
|
|
|
10) Goodin D, Ebers G, Traboulsee A, et al. The Interferon Beta-1b 16-Year Long-term Follow-up Study: Clinical Outcomes. Ann Neurol. 2006; 60: S35
|
|
|
|
|
|
11) Neuhaus O, Kieseier BC, Hartung HP. Immunosuppressive agents inmultiple sclerosis. Neurotherapeutics. 2007; 4: 654-60
|
|
|
|
|
|
12) Elovoaara I, Apostoloski S, von Doom P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008; 15: 893-908
|
|
|
|
|
|
13) Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006; 355: 1124-40
|
|
|
|
|
|
14) Muraro P, Bielekova B. Emerging therapies for multiple sclerosis. Neurotherapeutics. 2007; 4: 676-92
|
|
|
|
|
|
15) Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol. 2007; 62: 335-46
|
|
|
|
|
|
16) Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol. 2008; 7: 538-47
|
|
|
|
|
|
17) Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002; 360: 2018-25
|
|
|
|
|
|
18) Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008; 358: 676-88
|
|
|
|
|
|
19) Ravoris M, Confavreux C, Furlan R, et al. Secondary progressive multiple sclerosis: current knowledge and future challenge. Lancet Neurol. 2006; 5: 343-54
|
|
|
|
|
|
20) Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol. 2007; 6: 903-12
|
|
|
|
|
|
21) Boster A, Edan G, Frohman E, et al. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol. 2008; 7: 173-83
|
|
|
|
|
|
22) Stevenson VL, Playford ED. Rehabilitation and MS. Int MS J. 2007; 14: 85-92
|
|
|
|
|
|
23) Henze T. What is new in symptom management. Int MS J. 2007; 14: 22-7
|
|
|
|
|
|
24) Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of neuromyelitis optica: a study on antibody titre. Brain. 2007; 130: 1235-43
|
|
|
|
|
|
25) Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin-4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain. 2007; 130: 1224-34
|
|
|
|
|
|
26) Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Sclr. 2007; 13: 128-32
|
|
|
|
|
|
27) Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Sclr. 2007; 13: 968-74
|
|
|
|
|
|
28) Bergamaschi R. Immune agents for the treatment of Devic's neuromyelitis optica. Neurol Sci. 2007; 28: 238-40
|
|
|
|
|
|
29) Jacob A, Weinshenker BG, Violich I, et al. Treatment of Neuromyelitis Optica With Rituximab: Retrospective Analysis of 25 Patients. Arch Neurol. 2008. [Epub ahead of print]
|
|
|
|
|
|
30) 越智博文, 吉良潤一. 日本人MS患者におけるIFNβ製剤の使用実態に関する全国調査─中間報告─. 免疫性神経疾患に関する調査研究班平成19年度班会議抄録集. 2008. p. 52-3
|
|
|
|
|
|
31) Shimizu Y, Yokoyama K, Misu T, et al. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol. 2008; 255: 305-7
|
|
|
|
|